首页 | 本学科首页   官方微博 | 高级检索  
     

显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究
引用本文:Zhang GH,Shi DR,Liang XM,Hou JH,Kang SY,Zhu WD,Li XB,Shao Y,Chen LR,Zhou Y. 显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J]. 中华病理学杂志, 2006, 35(10): 580-583
作者姓名:Zhang GH  Shi DR  Liang XM  Hou JH  Kang SY  Zhu WD  Li XB  Shao Y  Chen LR  Zhou Y
作者单位:1. 200032,上海,复旦大学附属肿瘤医院病理科
2. 中山大学附属肿瘤医院病理科
3. 苏州大学附属第一医院病理科
4. 解放军第三○七医院病理科
5. 浙江大学附属第二医院病理科
摘    要:目的探讨显色原位杂交(CISH)在检测乳腺癌中HER2/neu基因扩增上的作用。方法挑选乳腺浸润性导管癌患者组织石蜡蜡块(回顾性255例,前瞻性271例),进行免疫组织化学(IHC)、CISH检测。15例回顾性标本送往德国HERA检测中心进行FISH检测。结果(1)回顾性病例中IHC阳性3+者CISH基因扩增率为91.6%(120/131),IHC2+者CISH基因扩增率为56.5%(39/69),IHC与CISH检测结果符合率为81.2%(207/255),两者明显相关(P〈0.01)。(2)前瞻性病例中IHC蛋白过表达率31.7%.CISH基因扩增率27.3%。IHC3+者CISH基因扩增率为91.4%(53/58),IHC2+者CISH基因扩增率为46.4%(13/28),IHC与CISH检测结果符合率为89.7%(243/271),两者明显相关(P〈0.01)。(3)经德国检测中心荧光原位杂交(FISH)检测的15例中14例和CISH结果完全一致,1例检测失败,而CISH为无扩增。(4)CISH检测基因扩增与雌激素受体(ER)、孕激素受体(PR)表达明显负相关(P值均〈0.01)。结论CISH检测HER2基因扩增结果与IHC检测蛋白过表达及FISH结果高度一致,CISH是检测HER2基因扩增的一项新技术。

关 键 词:乳腺肿瘤 基因  erbB-2 免疫组织化学 原位杂交
收稿时间:2006-03-03
修稿时间:2006-03-03

Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer
Zhang Gui-hong,Shi Da-ren,Liang Xiao-man,Hou Jing-hui,Kang Su-ya,Zhu Wei-dong,Li Xiao-bing,Shao Yun,Chen Li-rong,Zhou Yan. Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer[J]. Chinese Journal of Pathology, 2006, 35(10): 580-583
Authors:Zhang Gui-hong  Shi Da-ren  Liang Xiao-man  Hou Jing-hui  Kang Su-ya  Zhu Wei-dong  Li Xiao-bing  Shao Yun  Chen Li-rong  Zhou Yan
Affiliation:Department of Pathology, Cancer Hospital Affiliated to Fudan University, Shanghai 200032, China
Abstract:Objective Through comparision of HER2/neu oncogene detected by chromogenic in situ hybridization(CISH)and immunohistochemistry(IHC)in breast cancer,to explore the effect of CISH on detecting gene amplification of HER2.Methods Selected formalin-fixed paraffin-embedded breast samples whose pathological types were infiltrating ductal carcinomas(255 retrospective samples,271 prospective samples),and these samples were detected by IHC and CISH.Results(1)In the retrospective study,CISH identified gene amplification in 91.6% of IHC score 3+tumors(120/131)and in 56.5% of IHC score 2+tumors(39/69),thus the concordant ratio between IHC and CISH was 81.2% (207/255).The two results showed significant correlation(P<0.01).(2)In the prospective study,the ratio of HER2 protein over expression detected by IHC was 31.7%,the ratio of HER2 gene amplification detected by CISH was 27.3%.CISH identified gene amplification in 91.4% of IHC score 3+tumors (53/58)and in 46.4% of IHC score 2+tumors(13/28),Concordant ratio between IHC and CISH was 89.7%(243/271).Two results showed significant correlation(P<0.01).(3)Paired CISH/FISH results were concordant in 14 of 15 cases.The remaining case was detected by FISH,but showed no HER2 gene amplification by CISH.(4)The gene amplification by CISH had a significantly reverse correlation with ER and PR expression(P<0.01).Conclusions The results of HER2 gene amplification detected by CISH have high concordance with the results detectd by IHC and FISH.CISH is a novel technique for detecting HER2 gene amplification.
Keywords:Breast neoplasms    Genes, erbB-2    Immunohistoehemistry   In situ hybridization
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号